Abstract: The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex comprising acetaminophen and N-acetylcysteine is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon oral delivery of the vehicle to a target the enzyme is activated and releases acetaminophen and N-acetylcysteine from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.

Abstract: The present disclosure is directed to a method for increasing ketone levels in the bloodstream of a subject comprising administering to the subject an aqueous composition comprising a hydrogel, the hydrogel comprising: ?-hydroxybutyric acid (BHB); and carboxymethylcellulose or chitosan; wherein the BHB and the carboxymethylcellulose or chitosan form a hydrogel matrix, and the matrix has a pH in the aqueous composition of about 4.0±0.5.

Abstract: The present invention relates to an aqueous composition comprising in the aqueous phase microcapsules which comprise a shell and a core, where the core contains a pesticide; and a codispersant of the formula R—X, in which R has 6 to 10 carbon atoms and is alkyl, arylalkyl, or alkylaryl; X is —O—PO3H2, —CO2H, —O—SO3H, —SO3H, or salts thereof. The invention further relates to a method of preparing the composition by synthesizing the microcapsules in the aqueous phase in the presence of the codispersant; and to a method of controlling phytopathogenic fungi and/or undesired plant growth and/or undesired insect or mite attack and/or for regulating the growth of plants, wherein the composition is allowed to act on the respective pests, their environment or the crop plants to be protected from the respective pest, on the soil and/or on undesired plants and/or on the crop plants and/or on their environment.

Abstract: Provided are methods of making a pharmaceutical composition comprising: providing a matrix solution/suspension comprising a matrix former, a structure former, 0.1-1.5 wt. % anti-aerating agent, and a solvent; mixing a plurality of hydrophobic particles into the matrix solution/suspension to form a pharmaceutical suspension; and dosing the pharmaceutical suspension into preformed blister packs, wherein a dosed weight of the dosed pharmaceutical suspension is within 10 % of a target dosed weight.

Abstract: The present disclosure relates to an antifungal composition including propylene glycol, caprylic acid, and carvacrol as active ingredients.

Abstract: The present disclosure relates to a personal care device having a conditioning layer comprising a porous matrix comprising pores and having a hydrophobic conditioning agent fluid dispersed in the pores so that the conditioning agent can migrate to an exposed surface of the conditioning layer and then may be transferred to hair or skin surfaces. The conditioning layer may be prepared by preparing an immiscible conditioning composition comprising a hydrophilic material that is capable of being cured, and a hydrophobic conditioning agent. The immiscible composition is cured to form a conditioning layer that is a porous matrix formed from the hydrophilic material, the porous matrix having the hydrophobic conditioning agent fluid dispersed in the pores thereof.

Abstract: A delayed release delivery system comprises a hydrophilic core particle having surface pores and containing a liquid. The particle is encapsulated in a polymer having a hydrophobic backbone and hydrophilic pendant groups. At least some of the surface pores adjacent the hydrophilic pendant groups are blocked in the presence of water and unblocked in the absence of water. The treated particle contains liquid in a weight ratio of the liquid to the porous core particle of at least 400:1.

Abstract: A method of treating a microbial infection in a patient is provided, including steps of administering to a patient in need thereof a therapeutically effective amount of a metal-1-(2-hydroxyphenylazo)-2-naphthol (H2AZD) complex, wherein the metal is Fe(III), Ni(II), or Cu(II) and the metal is complexed with a 1-(2-hydroxyphenylazo)-2-naphthol (H2AZD) ligand.

Abstract: The invention relates to a pharmaceutical composition for the delivery of anaesthetic active substances. The pharmaceutical composition contains an anaesthetic active substance, an animal fat, and an anhydrous pharmaceutical ointment base. The anhydrous pharmaceutical ointment base can contain a sulfoxide, a carbonic acid amide, a dihydric alcohol, an aliphatic alcohol, and an omega-9 monounsaturated fatty acid.

Abstract: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer; (c) repeating step (b) at least 4 more times; and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

Abstract: The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

Abstract: Methods for inhibiting fungal secondary metabolisms are described. Secondary metabolisms inhibited by the methods can include those responsible for expression of mycotoxins such as aflatoxin. Methods can include inhibition of aflatoxin production without inhibiting fungal growth by contacting a fungus with a suspension including silver nanoparticles that can include a surface coating. The methods can be utilized in preventing fungal-caused destruction of plant species (e.g., crop species). Disclosed methods encompass utilization of silver nanoparticles at low concentrations of from about 10 picograms per liter to about 1 microgram per liter.

Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.

Abstract: The present disclosure describes treatment compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. The method utilizes a treatment composition that includes a cationic steroidal antimicrobial (CSA) compound, a poloxamer, and a carrier, which is administered to ciliated tissue, such as lung tissue, in order to prevent or treat a microbial infection by killing microbes associated with the ciliated tissue. The poloxamer forms micelles that encapsulate the CSA compound, the poloxamer being included in the treatment composition in an amount, by weight, that is about 100 to 1000 times the amount of the CSA compound.

Abstract: Compositions for the treatment of microbial infections and for the general well-being of a mammals' skin, nails, hooves, claws and/or feet, including a blend of copper sulfate, water, and at least one clay or clay-like material, methods for making such compositions, and methods for the use of such compositions to control, treat, prevent microbial infections of the same.

Abstract: The present invention is directed to a nerve regeneration conduit including a resorbable tube having a matrix therein. The matrix is characterized by substantially parallel, axially aligned pores extending the length of the matrix. The matrix is formed by the axial freezing of a slurry having little or no significant radial thermal gradient during the freezing process. The matrix is used to bridge the gap between the severed ends of a nerve and provide a scaffold for nerve regeneration.

Abstract: Compounds as depicted below and structural analogues thereof for activating invariant natural killer T cells (iNKT) cells are provided. Such compounds may be used to activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN?, IL-2, IL-4, IL-6 and TNF?. Activated iNKT cells may be used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Also provided are pharmaceutical compositions comprising such compounds.

Abstract: A method of using a strain of ciliated protozoan for promoting effect on germination and growth of plant seeds is provided. The ciliated protozoan is a Colpoda species JH2-5-4, with preservation number of China Center for Type Culture Collection (“CCTCC”) NO. C202229. A method of screening and selecting a highly efficient and active strain suitable for use as a microbial fertilizer in plant cultivation is provided. The selected ciliated protozoan strain shortens the germination time of plant seeds, promotes plant growth, and improves seedling survival rate.

Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.

Abstract: The present invention is directed to methods of enhancing toxicity of a glycolytic dependent compound towards a cancerous tissue and/or organ in a subject, the method being comprised of targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with the cancerous tissue and/or organ, and administering the glycolytic dependent compound to the subject by a systemic route.